{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T08:22:18Z","timestamp":1773044538433,"version":"3.50.1"},"reference-count":31,"publisher":"Wiley","issue":"s1","license":[{"start":{"date-parts":[[2001,12,21]],"date-time":"2001-12-21T00:00:00Z","timestamp":1008892800000},"content-version":"vor","delay-in-days":354,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2001,1]]},"abstract":"<jats:p>von Willebrand disease (vWD), the most common of the hereditary bleeding disorders, arises from quantitative or qualitative defects in von Willebrand factor (vWF). vWF is a multimeric plasma protein that plays a key role in primary and secondary haemostasis. In the current classification scheme, vWD is divided into six subtypes that are based on the nature of the vWF defect. Therapeutic strategies depend on the accurate identification of these subtypes. In most clinical situations, desmopressin is effective treatment for the great majority of patients with mild (type 1) disease, while replacement therapy with factor VIII\/vWF concentrates that contain high levels of vWF activity is required for most type 2 and nearly all type 3 vWD patients. Several factor VIII\/vWF replacement products are available, one of which (Humate P) has been approved for the treatment of vWD by the US Food and Drug Administration. Preliminary results of recent studies support the hypothesis that treatment with factor VIII\/vWF concentrates based upon the content of vWF activity as reflected in the ristocetin cofactor assay is practicable, safe and efficacious. The establishment of optimal treatment regimens with respect to dose intensity and duration will require further study.<\/jats:p>","DOI":"10.1046\/j.1365-2516.2001.00096.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T23:06:29Z","timestamp":1047423989000},"page":"10-15","source":"Crossref","is-referenced-by-count":12,"title":["Use of ristocetin cofactor activity in the management of von Willebrand disease"],"prefix":"10.1111","volume":"7","author":[{"given":"B.M.","family":"Ewenstein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,12,21]]},"reference":[{"key":"e_1_2_9_2_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.med.48.1.525"},{"key":"e_1_2_9_3_2","first-page":"1","article-title":"von Willebrand disease.","volume":"76","author":"Nichols WC","year":"1997","journal-title":"Rev Mol Med"},{"key":"e_1_2_9_4_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1613992"},{"key":"e_1_2_9_5_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.biochem.67.1.395"},{"key":"e_1_2_9_6_2","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1055\/s-0037-1615884","article-title":"Molecular genetics of von Willebrand disease.","volume":"82","author":"Ginsburg D.","year":"1999","journal-title":"Thromb Haemost"},{"key":"e_1_2_9_7_2","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1055\/s-0038-1642471","article-title":"A revised classification of von Willebrand disease.","volume":"71","author":"Sadler JE.","year":"1994","journal-title":"Thromb Haemostas"},{"key":"e_1_2_9_8_2","first-page":"152","article-title":"Determination of the von Willebrand\u2019s disease antigen (factor VIII\u2010related antigen) in plasma by quantitative immunoelectrophoresis.","volume":"86","author":"Zimmerman TS","year":"1975","journal-title":"J Lab Clin Med"},{"key":"e_1_2_9_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(90)90084-P"},{"key":"e_1_2_9_10_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI107464"},{"key":"e_1_2_9_11_2","first-page":"306","article-title":"A method for assaying von Willebrand factor (ristocetin cofactor).","volume":"34","author":"McFarlane DE","year":"1975","journal-title":"Thromb Diath Haemorrh"},{"key":"e_1_2_9_12_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI109795"},{"key":"e_1_2_9_13_2","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1182\/blood.V63.1.128.128","article-title":"Adhesion of platelets to human artery subendothelium: effect of factor VIII\u2013von Willebrand factor of various multimetric composition.","volume":"63","author":"Sixma JJ","year":"1984","journal-title":"Blood"},{"key":"e_1_2_9_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(96)00161-2"},{"key":"e_1_2_9_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1998.0040s3025.x"},{"key":"e_1_2_9_16_2","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1182\/blood.V69.6.1691.1691","article-title":"The effect of ABO blood group on the diagnosis of von Willebrand disease.","volume":"69","author":"Gill JC","year":"1987","journal-title":"Blood"},{"key":"e_1_2_9_17_2","first-page":"391","article-title":"von Willebrand disease masquerading as haemophilia A.","volume":"4","author":"Mazurier C.","year":"1992","journal-title":"Thromb Haemost"},{"key":"e_1_2_9_18_2","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1182\/blood.V90.7.2515","article-title":"Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years.","volume":"90","author":"Mannucci PM.","year":"1997","journal-title":"Blood"},{"key":"e_1_2_9_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(77)91197-7"},{"key":"e_1_2_9_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1992.tb04598.x"},{"key":"e_1_2_9_21_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.7.2428"},{"key":"e_1_2_9_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1992.tb01198.x"},{"key":"e_1_2_9_23_2","doi-asserted-by":"crossref","unstructured":"CohenAJ KesslerCM&EwensteinBMon behalf of the Hemophilia Research Society of North America. Management of von Willebrand disease: a survey on current clinical practice from the Hemophilia Centers of North America.Haemophilia2001;7: in press.","DOI":"10.1046\/j.1365-2516.2001.00498.x"},{"key":"e_1_2_9_24_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1998.0040s3048.x"},{"key":"e_1_2_9_25_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1998.0040s3011.x"},{"key":"e_1_2_9_26_2","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1182\/blood.V79.12.3130.bloodjournal79123130","article-title":"Comparison of four virus\u2010inactivated plasma concentrates for treatment of severe von Willebrand disease: a cross\u2010over randomized trial.","volume":"79","author":"Mannucci PM","year":"1992","journal-title":"Blood"},{"key":"e_1_2_9_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830450303"},{"key":"e_1_2_9_28_2","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1182\/blood.V91.4.1325","article-title":"Screening for von Willebrand disease with a new analyzer utilizing high shear stress: a study of 60 cases.","volume":"91","author":"Fressinaud E","year":"1998","journal-title":"Blood"},{"key":"e_1_2_9_29_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1998.0040s3001.x"},{"key":"e_1_2_9_30_2","first-page":"227","article-title":"Efficacy and safety of Haemate\u2010P in Canadian von Willebrand disease patients.","volume":"6","author":"Lillicrap D","year":"2000","journal-title":"Haemophilia"},{"key":"e_1_2_9_31_2","first-page":"227","article-title":"Treatment of von Willebrand disease (vWD) in patients with urgent life\u2010 or limb\u2010threatening bleeding or emergent surgery with Humate P (factor VIII\/vWF concentrate).","volume":"6","author":"Ewenstein BM","year":"2000","journal-title":"Haemophilia"},{"key":"e_1_2_9_32_2","unstructured":"MannucciPM ChediakJ&ByrnesJet al.A high purity factor VIII concentrate in the treatment of von Willebrand\u2019s disease.Thromb Haemost1999;82(Abstract)."}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2516.2001.00096.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2516.2001.00096.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2516.2001.00096.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T07:58:52Z","timestamp":1695801532000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2516.2001.00096.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,1]]},"references-count":31,"journal-issue":{"issue":"s1","published-print":{"date-parts":[[2001,1]]}},"alternative-id":["10.1046\/j.1365-2516.2001.00096.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2516.2001.00096.x","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,1]]}}}